Chimerix, Inc. (CMRX) Expected to Announce Earnings of -$0.49 Per Share
Wall Street brokerages predict that Chimerix, Inc. (NASDAQ:CMRX) will report earnings per share (EPS) of ($0.49) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Chimerix’s earnings, with the lowest EPS estimate coming in at ($0.56) and the highest estimate coming in at ($0.43). Chimerix posted earnings of ($0.32) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 53.1%. The company is scheduled to report its next earnings report on Thursday, March 1st.
On average, analysts expect that Chimerix will report full year earnings of ($1.60) per share for the current fiscal year, with EPS estimates ranging from ($1.64) to ($1.56). For the next financial year, analysts anticipate that the business will post earnings of ($1.85) per share, with EPS estimates ranging from ($2.12) to ($1.50). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Chimerix.
Chimerix (NASDAQ:CMRX) last issued its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.06. Chimerix had a negative net margin of 1,440.67% and a negative return on equity of 26.00%. The business had revenue of $0.90 million during the quarter, compared to analysts’ expectations of $0.81 million.
In other news, insider Linda M. Richardson sold 19,833 shares of the firm’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $4.47, for a total value of $88,653.51. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 4.40% of the stock is currently owned by company insiders.
Several institutional investors have recently added to or reduced their stakes in CMRX. Metropolitan Life Insurance Co. NY bought a new stake in Chimerix during the 1st quarter valued at about $226,000. Dimensional Fund Advisors LP lifted its holdings in Chimerix by 114.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,043,336 shares of the biopharmaceutical company’s stock valued at $6,656,000 after buying an additional 557,927 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Chimerix by 11.7% during the 1st quarter. Geode Capital Management LLC now owns 341,238 shares of the biopharmaceutical company’s stock valued at $2,177,000 after buying an additional 35,752 shares in the last quarter. AXA lifted its holdings in Chimerix by 284.9% during the 2nd quarter. AXA now owns 258,573 shares of the biopharmaceutical company’s stock valued at $1,409,000 after buying an additional 191,400 shares in the last quarter. Finally, Morgan Stanley lifted its holdings in Chimerix by 203.9% during the 1st quarter. Morgan Stanley now owns 618,074 shares of the biopharmaceutical company’s stock valued at $3,944,000 after buying an additional 414,717 shares in the last quarter. Hedge funds and other institutional investors own 70.36% of the company’s stock.
Shares of Chimerix (NASDAQ CMRX) traded down $0.07 during trading hours on Wednesday, hitting $4.39. 236,100 shares of the company’s stock were exchanged, compared to its average volume of 299,999. Chimerix has a 1-year low of $4.17 and a 1-year high of $6.64.
ILLEGAL ACTIVITY NOTICE: “Chimerix, Inc. (CMRX) Expected to Announce Earnings of -$0.49 Per Share” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/13/chimerix-inc-cmrx-expected-to-announce-earnings-of-0-49-per-share.html.
Chimerix Company Profile
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.